Drug evaluation: Adecatumumab, an engineered human anti-EpCAM antibody

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 190-196

  Kirman, Irena ^a   Whelan, Richard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADECATUMUMAB; EPITHELIAL CELL ADHESION MOLECULE;

ABDOMINAL PAIN; BREAST ADENOCARCINOMA; CHILL; CLINICAL TRIAL; COLD; DIARRHEA; DRUG SCREENING; EPITHELIUM CELL; FEVER; HOT FLUSH; HUMAN; HYPERTENSION; NAUSEA; NONHUMAN; PROSTATE ADENOCARCINOMA; REVIEW; RIGOR; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SWEATING; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HUMANS; PATENTS; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247231674     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 411255 Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H PROC NATL ACAD SCI USA 1995 92 11 4773-4777
2. 431108 Micromet has initiated clinical trials with its human antibody MT201 for treatment of prostate cancer. Micromet GmbH PRESS RELEASE 2001 October 29
3. 437373 JPMorgan Hambrecht & Quist 20th Healthcare Conference: Micromet AG. Micromet AG COMPANY PRESENTATION 2002 January 08
4. 452530 Safety, tolerability, and maximum tolerated dose of an intravenously administered human-engineered monoclonal antibody, ING-1(heMAb), in patients with advanced adenocarcinomas. de Bono JS, Forero A, Hammond LA, Patnaik A, Takimoto C, LoBuglio A, Mays T, Rowinsky EK, Bauer R, Van Hove G, Tolcher A PROC AM SOC CLIN ONCOL 2002 21 1 Abs 34
5. 459360 In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakan F INT J CANCER 2002 100 1 101-110
6. 462892 Novuspharma to co-develop Micromet's human antibody MT201 for the treatment of cancer. Novuspharma SpA PRESS RELEASE 2002 September 02
7. 500515 Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R J CANCER RES CLIN ONCOL 2003 129 6 341-348
8. 503996 Cambridge Antibody Technology announces product licence agreement with Micromet AG. Cambridge Antibody Technology Group plc PRESS RELEASE 2003 September 03
9. 518072 Cell Therapeutics Inc (CTI) and Novuspharma SpA complete merger. Cell Therapeutics Inc PRESS RELEASE 2004 January 02
10. 526850 Micromet starts MT-201 phase II trial in breast cancer. Micromet AG PRESS RELEASE 2004 March 09
11. 545323 Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC). Peters M, Dasilva A, Weckermann D, Oberneder R, Ebner B, Kirchinger P, Fetter A, Köhne-Volland R, Baeuerle P, Gjorstrup P PROC AM SOC CLIN ONCOL 2004 23 Abs 2600
12. 572513 FDA approves Micromet's phase II breast cancer study. Micromet AG PRESS RELEASE 2004 November 23
13. 574699 Serono and Micromet to collaborate in development and commercialization of novel anti-cancer drug. Serono SA PRESS RELEASE 2004 December 07
14. 583053 Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ BR J CANCER 2005 92 11 342-349
15. 588470 First trial of a phase II program covering major carcinoma indications. Micromet AG PRESS RELEASE 2004 February 11
16. 598162 Micromet begins phase I trial of MT-201 with Taxotere. Micromet AG PRESS RELEASE 2005 April 27
17. 656351 Monoclonal antibody therapy of cancer. Adams GP, Weiner LM NAT BIOTECHNOL 2005 23 9 1147-1157
18. 665961 Micromet and CancerVax complete merger to form Micromet Inc. CancerVax Corp PRESS RELEASE 2006 May 05
19. 674049 Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ, Warnaar SO AM J PATHOL 1996 148 3 865-875
20. 674052 Long-term prognosis for colon cancer related to consistent radical surgery: Multivariate analysis of clinical, surgical, and pathologic variables. Jagoditsch M, Lisborg PH, Jatzko GR, Wette V, Kropfitsch G, Denk H, Klimpfinger M, Stettner HM WORLD J SURG 2000 24 10 1264-1270
21. 674057 Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D et al LANCET 2002 360 9334 671-677
22. 674058 Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study. Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, Fackler-Schwalbe I, Bornbusch D, Gonnermann M, Wojatschek C et al ONKOLOGIE 2005 28 6-7 347-350
23. 676822 The biology of the 17-1A antigen (Ep-CAM). Balzar M, Winter MJ, de Boer CJ, Litvinov SV J MOL MED 1999 77 10 699-712
24. 677145 United States cancer statistics: 2002 Incidence and mortality. US Cancer Statistics Working Group COMPANY WORLD WIDE WEB SITE 2005 1-702
25. 720507 Micromet's adecatumumab fails in phase II cancer trials. Serono SA PRESS RELEASE 2006 October 02
26. 738728 A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E EUR J CANCER 2006 42 15 2530-2538
27. 748070 Micromet Inc receives $10 million milestone payment from Serono for completion of phase 2 clinical trials. Micromet Inc PRESS RELEASE 2006 December 04
28. 748767 Micromet and Serono amend adecatumumab agreement. Micromet Inc PRESS RELEASE 2006 December 05
29. 765567 Anti-self antibodies selected from a human IgD heavy chain repertoire: A novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Raum T, Gruber R, Riethmuller G, Kufer P CANCER IMMUNOL IMMUNOTHER 2001 50 3 141-150
30. 765586 High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS MOL IMMUNOL 2006 43 8 1183-1193
31. 765587 ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB et al CLIN CANCER RES 2004 10 22 7555-7565
32. 765588 A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Mitchell PL, Basser R, Chipman M, Grigg A, Mansfield R, Cebon J, Davis ID, Appia F, Green M ANN ONCOL 2004 15 4 585-589
33. 765590 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E et al LANCET 2005 366 9503 2087-2106
34. 765594 The National Prostate Cancer Register in Sweden 1998-2002: Trends in incidence, treatment and survival. Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Stattin P, Tornblom M, Johansson JE SCAND J UROL NEPHROL 2005 39 2 117-123
35. 765597 Cardiac toxicity of high-dose chemotherapy. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V BONE MARROW TRANSPLANT 2005 35 4 323-334
36. 765605 Neurological complications of cancer chemotherapy. Hildebrand J CURR OPIN ONCOL 2006 18 4 321-324
37. 765611 Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA NUCL MED COMMUN 1994 15 8 613-627
38. 770273 Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G et al J CLIN ONCOL 2006 24 24 3984-3990
39. 770274 Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT J CLIN ONCOL 2006 24 24 3973-3978
40. 770276 Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L et al EUR J CANCER 2007 43 4 725-735
41. 770278 The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O ONCOGENE 2004 23 34 5748-5758
42. 770279 The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eskens FA, Verweij J EUR J CANCER 2006 42 18 3127-3139
43. 770280 Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Van Cutsem E ONCOLOGIST 2006 11 9 1010-1017